Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Gains from Sales and Divestitures (2017 - 2025)

Puma Biotechnology's Gains from Sales and Divestitures history spans 9 years, with the latest figure at $1.2 million for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures fell 10.65% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $1.2 million, down 10.65%, while the annual FY2025 figure was $1.2 million, 10.65% down from the prior year.
  • Gains from Sales and Divestitures reached $1.2 million in Q4 2025 per PBYI's latest filing, up from $1.2 million in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $1.4 million in Q4 2024 to a low of $189625.0 in Q1 2022.
  • Average Gains from Sales and Divestitures over 5 years is $828991.2, with a median of $793894.0 recorded in 2021.
  • Peak YoY movement for Gains from Sales and Divestitures: soared 109.74% in 2021, then decreased 20.48% in 2022.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $1.1 million in 2021, then dropped by 6.55% to $1.0 million in 2022, then grew by 27.84% to $1.3 million in 2023, then rose by 7.21% to $1.4 million in 2024, then dropped by 10.65% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Gains from Sales and Divestitures are $1.2 million (Q4 2025), $1.2 million (Q3 2025), and $731009.0 (Q2 2025).